Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,081 to 1,100 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic Polymerase Chain Reaction (PCR)-Confirmed Primary C. Difficile Infection (CDI) Cases | 34 of 6,173 16 of 3,085 | 0.0 points -0.3 to 0.3 | 9,258 | NCT01887912 Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection |
| With Metabolic Syndrome vs Without Metabolic Syndrome: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome) | 92 of 1,716 852 of 7,535 | -5.9 points -7.2 to -4.6 | 9,251 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Chronic Kidney Disease vs Without Chronic Kidney Disease: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Chronic Kidney Disease) | 24 of 1,034 920 of 8,217 | -8.9 points -9.9 to -7.6 | 9,251 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Diabetes Mellitus vs Without Diabetes Mellitus: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Diabetes Mellitus) | 52 of 2,247 892 of 7,004 | -10.4 points -11.4 to -9.4 | 9,251 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Myocardial Infarction vs Without Myocardial Infarction: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Myocardial Infarction) | 1 of 55 943 of 9,196 | -8.4 points -10.1 to -0.6 | 9,251 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| Prasugrel vs Clopidogrel: serious adverse events | 1,573 of 4,623 1,594 of 4,617 | -0.5 points -2.4 to 1.4 | 9,240 | NCT00699998 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects |
| Tranexamic Acid vs Placebo: Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery | 339 of 4,641 368 of 4,573 | -0.7 points -1.8 to 0.3 | 9,214 | NCT03364491 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean |
| C. Difficile Vaccine Group vs Placebo Group: deaths from any cause | 255 of 6,113 127 of 3,057 | 0.0 points -0.9 to 0.9 | 9,170 | NCT01887912 Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection |
| C. Difficile Vaccine Group vs Placebo Group: serious adverse events | 1,662 of 6,113 851 of 3,057 | -0.6 points -2.6 to 1.3 | 9,170 | NCT01887912 Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection |
| Fluzone® High Dose vs Fluzone®: serious adverse events | 493 of 6,108 236 of 3,050 | 0.3 points -0.9 to 1.5 | 9,158 | NCT00976027 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older |
| Automated Call vs Text Messaging: Percentage of Tested Patients | 12 of 4,489 25 of 4,631 | -0.3 points -0.6 to -0.0 | 9,120 | NCT05315908 COVID-19 Testing in Underserved and Vulnerable Populations |
| Automated Call vs Text Messaging: Number (%) Tested (Total and by Clinic) | 12 of 4,489 25 of 4,631 | -0.3 points -0.6 to -0.0 | 9,120 | NCT05315908 COVID-19 Testing in Underserved and Vulnerable Populations |
| S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Severe COVID-19 in the Initial Vaccination Period With Onset at Least 14 Days Following Second Vaccination Regardless of Serostatus or PCR Status at Baseline | 0 of 6,049 1 of 3,034 | -0.0 points -0.2 to 0.0 | 9,083 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
| S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Symptomatic COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline With Onset at Least 14 Days Following Second Vaccination | 331 of 6,023 242 of 3,012 | -2.5 points -3.7 to -1.4 | 9,035 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
| Irbesartan vs Placebo: First Hospitalisation for Heart Failure (HF) | 482 of 4,518 551 of 4,498 | -1.6 points -2.9 to -0.3 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Irbesartan vs Placebo: Death From Any Cause | 949 of 4,518 929 of 4,498 | 0.4 points -1.3 to 2.0 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Irbesartan vs Placebo: First Occurrence of Stroke | 379 of 4,518 411 of 4,498 | -0.7 points -1.9 to 0.4 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Irbesartan vs Placebo: First Hospitalisation for Other Cardiovascular (CV) Cause | 1,186 of 4,518 1,174 of 4,498 | 0.2 points -1.7 to 2.0 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Irbesartan vs Placebo: First Occurrence of Any Heart Failure (HF) Episode | 699 of 4,518 767 of 4,498 | -1.6 points -3.1 to -0.1 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Irbesartan vs Placebo: serious adverse events | 1,409 of 4,518 1,446 of 4,498 | -1.0 points -2.9 to 1.0 | 9,016 | NCT00249795 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=55
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01887912-b6fb6639",
"title": "C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic Polymerase Chain Reaction (PCR)-Confirmed Primary C. Difficile Infection (CDI) Cases",
"summary": "34 of 6173 against 16 of 3085; risk difference 0.0 points, 95% interval -0.3 to 0.3; NCT01887912, Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",
"record": "/library/comparisons/NCT01887912-b6fb6639",
"nct_id": "NCT01887912",
"kind": "outcome",
"participants": 9258,
"risk_difference": {
"value": 0.0003214710582840896,
"lower": -0.003260031682308312,
"upper": 0.0032731228641439485
},
"group_1": "34 of 6,173",
"group_2": "16 of 3,085",
"difference": "0.0 points",
"interval": "-0.3 to 0.3",
"trial_title": "Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection"
},
{
"id": "NCT01252563-4a1fd637",
"title": "With Metabolic Syndrome vs Without Metabolic Syndrome: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)",
"summary": "92 of 1716 against 852 of 7535; risk difference -5.9 points, 95% interval -7.2 to -4.6; NCT01252563, Amlodipine 10mg Drug Use Investigation",
"record": "/library/comparisons/NCT01252563-4a1fd637",
"nct_id": "NCT01252563",
"kind": "outcome",
"participants": 9251,
"risk_difference": {
"value": -0.05945927551766968,
"lower": -0.07162466373102162,
"upper": -0.04585780475212915
},
"group_1": "92 of 1,716",
"group_2": "852 of 7,535",
"difference": "-5.9 points",
"interval": "-7.2 to -4.6",
"trial_title": "Amlodipine 10mg Drug Use Investigation"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=56",
"request_id": "UmKl5Yq692GyMYrg"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant